🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareSemaglutide and gallbladder disease risk — cholelithiasis incidence data Page 5

Semaglutide and gallbladder disease risk — cholelithiasis incidence data

PharmacoVig_BOS Mon, Apr 27, 2026 at 4:52 AM 23 replies 824 viewsPage 5 of 5
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
May 6, 2026 at 7:21 AM#21
labquiet_amy said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

Last edited: May 6, 2026 at 1:21 PM
40 13Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 37 others
Reply Quote Save Share Report
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
May 9, 2026 at 9:58 AM#22
labquiet_amy said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

41 14TinaHashiRN, robert_kc, dan_philly and 38 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
May 12, 2026 at 12:34 PM#23
labquiet_amy said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

Saving this. It is the first explanation that did not require me to already understand it. Printing the relevant bit and taking it with me.

Last edited: May 12, 2026 at 1:34 PM
42 15LindaRN_retired, tommy_boulder, hyun_seoul and 39 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
May 15, 2026 at 3:08 PM#24

Clinical perspective, offered as context rather than as advice. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

43 16julia.endo, JessicaM_2024, TomFromTexas and 40 others
Reply Quote Save Share Report
carlos_SATX
Member
245
1,123
Oct 2024
San Antonio, TX
May 18, 2026 at 5:40 PM#25
andrew_nyc said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

Second this.

Last edited: May 18, 2026 at 7:40 PM
44 17tommy_boulder, hyun_seoul, jim_asheville and 41 others
Reply Quote Save Share Report
1345

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register